Iron replacement therapy: Do we need new guidelines?

Current Opinion in Gastroenterology

Volumn 32, Issue 2, 2016, Pages 128-135

  Nielsen, Ole Haagen ^a   Coskun, Mehmet ^a   Weiss, Günter ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

anemia; guidelines; inflammation; iron deficiency; therapy

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; FUMARIC ACID; GLUCONIC ACID; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; UNCLASSIFIED DRUG; TRACE ELEMENT;

FOLLOW UP; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON REPLACEMENT THERAPY; IRON THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RELAPSE; REVIEW; SUBSTITUTION THERAPY; ANEMIA, IRON-DEFICIENCY; EVIDENCE BASED MEDICINE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREVALENCE; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; EVIDENCE-BASED MEDICINE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SEVERITY OF ILLNESS INDEX; TRACE ELEMENTS;

EID: 84956914560     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000247     Document Type: Review

References (68)

1. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123:615-624.
2. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2013; 9:205-215.
3. Nairz M, Schroll A, Demetz E, et al. Ride on the ferrous wheel: The cycle of iron in macrophages in health and disease. Immunobiology 2015; 220:280-294.
4. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372:1832-1843.
5. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010; 142:24-38.
6. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 2014; 5:750-760.
7. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012; 51:5705-5724.
8. Coad J, Conlon C. Iron deficiency in women: Assessment, causes and consequences. Curr Opin Clin Nutr Metab Care 2011; 14:625-634.
9. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341:1986-1995.
10. McDermid JM, Lonnerdal B. Iron. Adv Nutr 2012; 3:532-533.
11. Hurrell R, Egli I. Iron bioavailability and dietary reference values. Am J Clin Nutr 2010; 91:1461S-1467S.
12. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823:1434-1443.
13. Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172:5025-5028.
14. Koehler K, Braun H, Achtzehn S, et al. Iron status in elite young athletes: gender-dependent influences of diet and exercise. Eur J Appl Physiol 2012; 112:513-523.
15. Peeling P, Sim M, Badenhorst CE, et al. Iron status and the acute postexercise hepcidin response in athletes. PLoS One 2014; 9:e93002.
16. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113:5277-5286.
17. Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325:877-880.
18. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46:678-684.
19. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974; 290:1213-1216.
20. Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44:45-51.
21. Weiss G. Anemia of chronic disorders: new diagnostic tools and new treatment strategies. Semin Hematol 2015; 52:313-320.
22. van Santen S, de MQ, Oosting JD, et al. Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica 2014; 99:e171-e173.
23. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11:14-23.
24. Archer NM, Brugnara C. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci 2015; 52:256-272.
25. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16:1416-1423.
26. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28:303-308.
27. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116:4754-4761.
28. Theurl I, Schroll A, Nairz M, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 2011; 96:1761-1769.
29. van Santen S, van Dongen-Lases EC, de VF, et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011; 63:3672-3680.
30. Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: A clinical overview. Scient World J 2012; 2012/:846824.
31. Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. J Trace Elem Med Biol 2012; 26:115-119.
32. Lane DJ, Richardson DR. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! Free Radic Biol Med 2014; 75:69-83.
33. Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy. A doubleblind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459:3-10.
34. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126:1981-1989.
35. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88:97-101.
36. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18:319-332.
37. Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-Associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104:1460-1467.
38. Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 2014; 89:7-12.
39. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologia 2014; 99:1671-1676.
40. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010:338-347.
41. Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2013; 6:61-70.
42. Gomollon F, Gisbert JP. Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013; 29:201-207.
43. Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: A systematic review. Medicine (Baltimore) 2015; 94:e963.
44. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-382.
45. Chertow GM, Winkelmayer WC. On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol 2010; 85:643-644.
46. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83:580-588.
47. EMA: New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-And-events/news/2013/06/news-detail-001833. jsp&mid=WC0b01ac058004d5c1. [Assessed 07-11-2015]
48. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222-3227.
49. Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J 2013; 34:827-834.
50. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Lowdose iron therapy is effective in octogenarians. Am J Med 2005; 118:1142-1147.
51. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014; 34:707-723.
52. Prentice AM, Doherty CP, Abrams SA, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012; 119:1922-1928.
53. Sonnweber T, Theurl I, Seifert M, et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 2011; 26:977-987.
54. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006; 367:133-143.
55. Soofi S, Cousens S, Iqbal SP, et al. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: A cluster-randomised trial. Lancet 2013; 382:29-40.
56. Clark MA, Goheen MM, Fulford A, et al. Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. Nat Commun 2014; 5:4446.
57. Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015; 64:731-742.
58. Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014; 38:1202-1234.
59. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108:1877-1888.
60. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015; 21:579-588.
61. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-590.
62. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19:121-132.
63. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
64. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:269-277.
65. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000; 46 (Suppl 3-4):IV1-IV5.
66. Fernandez-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol 2014; 2:513-526.
67. Wilson K, Sloan JM. Iron-deficiency anemia. N Engl J Med 2015; 373: 485.
68. Zitt E, Sturm G, Kronenberg F, et al. Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS One 2014; 9:e114144.